<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498534</url>
  </required_header>
  <id_info>
    <org_study_id>CI-543</org_study_id>
    <nct_id>NCT03498534</nct_id>
  </id_info>
  <brief_title>Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis</brief_title>
  <official_title>Evaluation of the Impact of Diabetes Control on Transmission and Development of Tuberculosis in the General Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Salud Publica, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical test (essay) randomized to evaluate the toxicity adherence and efficiency of the
      chemoprophylaxis of tuberculosis (TB) in subjects with Diabetes Mellitus (DM) and latent TB.
      (600 subjects followed(continued) by 15 months). 3rd stage. Patients with DM and TB will be
      included to determine if the strict control of the dm achieved in clinics of the first level
      of attention improves clinical manifestations of tb, the result of treatment, the frequency
      of relapses, the mortality and the transmission to contacts.

      Elispot will be used to measure TB development and the time for the bacteriological
      negativization and biochemical parameters as well as tuberculin skin test (TST), quantiferon,
      in contacts. (160 patients 600 contacts followed(continued) for 12 months). additional there
      will be evaluated the socioeconomic impact of both diseases and his(her) control. 1er year:
      transverse study and recruitment years 2 and 3 participants' follow-ups in clinical
      tests(essays).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to administrative procedures
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of active TB</measure>
    <time_frame>6 months</time_frame>
    <description>Researchers will test patients at day 0 and day 180 of treatment to detect the development of active TB</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Latent Tuberculosis</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Patients with a -TST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with a +TST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300Mg Tab</intervention_name>
    <description>-TST tests will receive isoniazid 300Mg Tab for 6 months</description>
    <arm_group_label>Patients with a -TST</arm_group_label>
    <other_name>Isoniazid 300 mgs.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300 MG</intervention_name>
    <description>+ TST test will receive isoniazid 300MG Tab for 6 months</description>
    <arm_group_label>Patients with a +TST</arm_group_label>
    <other_name>Isoniazid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid 300 MG</intervention_name>
    <description>HIV positive patient will receive isoniazid 300MGTab for 6 months</description>
    <arm_group_label>HIV positive patients</arm_group_label>
    <other_name>Isoniazid 300 mg per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive HIV TST tuberculin

        Exclusion Criteria:

          -  Previous TB treatment Hepatic failure AIDS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garcia-Garcia Lourdes, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of public Health</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Salud Publica, Mexico</investigator_affiliation>
    <investigator_full_name>Ma. de Lourdes Garcia Garcia</investigator_full_name>
    <investigator_title>Director of the Center of Research in Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Latent infection</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Interferon gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

